Results 71 to 80 of about 122,678 (147)

PENGUKURAN ANTIBODI KUANTITATIF ANTIBODI ANTI-SARS-COV-2

Majalah Ilmiah METHODA, 2021
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19). Molecular-based testing is used to diagnose COVID-19, and serologic testing of antibodies specific to SARS-CoV-2 is used to detect past infection. While most serologic assays are qualitative, a quantitative serologic assay was
openaire   +2 more sources

Novel Trispecific Neutralizing Antibodies With Enhanced Potency and Breadth Against Pan‐Sarbecoviruses

MedComm
The ongoing emergence of new variants of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) underscores the urgent need for developing antivirals targeting both SARS‐CoV‐2 variants and related sarbecoviruses.
Rui Qiao, Yuanchen Liu, Qiyu Mao, Jiayan Li, Yinying Lu, Jialu Shi, Chen Li, Jizhen Yu, Jiami Gong, Xun Wang, Yuchen Shao, Lei Sun, Wenhong Zhang, Hongjie Yu, Hin Chu, Pengfei Wang, Xiaoyu Zhao   +16 more
doaj   +1 more source

Virus antibodies after SARS‐CoV‐2 infection [PDF]

Acta Paediatrica, 2021
Rujittika, Mungmunpuntipantip, Viroj, Wiwanitkit   +1 more
openaire   +2 more sources

Comparison of Four SARS-CoV-2 Neutralization Assays

Vaccines, 2020
Neutralizing antibodies are a major correlate of protection for many viruses including the novel coronavirus SARS-CoV-2. Thus, vaccine candidates should potently induce neutralizing antibodies to render effective protection from infection.
Lydia Riepler, Annika Rössler, Albert Falch, André Volland, Wegene Borena, Dorothee von Laer, Janine Kimpel   +6 more
doaj   +1 more source

Seroprevalence of SARS-CoV-2 Infection Among People Living with HIV in Libreville, Gabon

COVID
(1) Objectives: The burden of SARS-CoV-2 infection in people living with HIV (PLHIV) in Gabon is unknown. (2) Methods: We conducted a cross-sectional seroprevalence study of SARS-CoV-2 immunoglobulin (Ig) G/M antibodies in PLHIV in Libreville from April ...
Samira Zoa-Assoumou, Hervé M’boyis-Kandem, Pelagie Saphou-Damon, Davy Ulrich Leger Mouangala, Guy-Francis Nzengui, Marina Mbani-Okoumba, Claudine Kombila-Koumavor, Gael Mourembou, Brama Ibrahim, Angelique Ndjoyi-Mbiguino   +9 more
doaj   +1 more source

Antibodies, epicenter of SARS-CoV-2 immunology [PDF]

Cell Death & Differentiation, 2021
Pecetta, Simone, Pizza, Mariagrazia, Sala, Claudia, Andreano, Emanuele, Pileri, Piero, Troisi, Marco, Pantano, Elisa, Manganaro, Noemi, Rappuoli, Rino   +8 more
openaire   +2 more sources

Testing for antibodies to SARS-CoV-2 [PDF]

BMJ, 2020
Gill, Dipender, Ponsford, Mark J
openaire   +2 more sources

Developing antibody tests for SARS-CoV-2 [PDF]

The Lancet, 2020
openaire   +2 more sources

Delineating the functional activity of antibodies with cross-reactivity to SARS-CoV-2, SARS-CoV-1 and related sarbecoviruses.

PLoS Pathogens
The recurring spillover of pathogenic coronaviruses and demonstrated capacity of sarbecoviruses, such SARS-CoV-2, to rapidly evolve in humans underscores the need to better understand immune responses to this virus family.
Felicitas Ruiz, William B Foreman, Michelle Lilly, Viren A Baharani, Delphine M Depierreux, Vrasha Chohan, Ashley L Taylor, Jamie Guenthoer, Duncan Ralph, Frederick A Matsen Iv, Helen Y Chu, Paul D Bieniasz, Marceline Côté, Tyler N Starr, Julie Overbaugh   +14 more
doaj   +1 more source

SARS-CoV-2 and enhancing antibodies

Journal of Clinical Virology, 2020
openaire   +2 more sources